ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bracco and Novartis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BraccoNovartis
studies on the registry663,900
open to participants now5212
phase 3 studies under way194
reach primary completion within a year0125
programswith a study of their own in two years377+7 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBraccoNovartis
Phase 100%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
Phase 2

Bracco: 2 of its 3 programs at phase 2

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2
67%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. arumakimigphase 2
  4. QCZ484phase 2
  5. DDY391phase 2

and 30 more — sign in to see them all

45%
Phase 300%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
Approved, new studies

Bracco: 1 of its 3 programs at approved, new studies

  1. fluciclovine F-18approved, new study
33%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bracco0 readouts · 0 phase 3············
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · Jan 4 · NCT05397496
  2. opnurasibphase 3 · Jan 25 · NCT04699188
  3. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 2 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bracco

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 5

  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 5

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionBraccoNovartis
Prostatic Neoplasmsboth · compare here

Bracco in Prostatic Neoplasms: 2 programs

  1. Gallium-68phase 2
  2. fluciclovine F-18approved, new study

Their studies: Bracco’s studies of Prostatic Neoplasms in search

Novartis in Prostatic Neoplasms: 13 programs

  1. Atrasentanphase 3
  2. actinium AC-225 vipivotide tetraxetanphase 3
  3. Gallium-68phase 3
  4. ARPIphase 3
  5. Lutetium-177phase 2

and 8 more — sign in to see them all

Their studies: Novartis’s studies of Prostatic Neoplasms in search

Breast Neoplasmsboth · compare here

Bracco in Breast Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Breast Neoplasms in search

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Bracco in Colorectal Neoplasms: 2 programs

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2

Their studies: Bracco’s studies of Colorectal Neoplasms in search

Novartis in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Colorectal Neoplasms in search

Carcinoma, Renal Cellboth · compare here

Bracco in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Carcinoma, Renal Cell in search

Novartis in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Carcinoma, Renal Cell in search

Urinary Bladder Neoplasmsboth · compare here

Bracco in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Urinary Bladder Neoplasms in search

Novartis in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Urinary Bladder Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Bracco 2 of 3 · Novartis 56 of 77 programs (17 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7).